Martin Perry, MBChB, BSc, MMEd, FRCP, clinical medical director for the National Health Service in Greater Glasgow and Clyde, Scotland, explains frontline care with biosimilars during COVID-19.
The Center for Biosimilars® spoke with Martin Perry, MBChB, BSc, MMEd, FRCP, Clinical Medical Director for the National Health Service (NHS) in the Greater Glasgow and Clyde region of Scotland about biosimilar savings and access during COVID-19. Perry was a presenter on the topic during the recent Terrapinn Festival of Biologics meeting in Basel, Switzerland.
Perry oversaw a COVID-19 ward and during this talk with The Center for Biosimilars® Senior Editor Tony Hagen, he explains the challenges of providing treatment for patients. He also sheds light on the United Kingdom's unique system of biosimilar choice and pricing. Access to biosimilars has broadened in the United Kingdom, partly due to the lower cost of these agents; but overall spending on biologics and specialty drugs is on the increase there, as in the United States.
Perry also addresses switching patients from reference products to biosimilars and patient acceptance. Nocebo, or the potential for patients with poor attitudes toward biosimilars to influence their own outcomes, is a very real concern, Perry explains, underscoring the need for strong educational efforts to support biosimilar use.
Brexit, or the United Kingdom's separation from the economic apron strings of the European Union, is well along since the beginning of 2021, and this has resulted in "no notable difference" in biosimilar supply, Perry reports.
The UK continues to get a handle on the COVID-19 pandemic, and its most recent spike in cases is on the wane; and in the Glasgow/Clyde area the infection rate hasn't been as serious as in the Southeast (London), partly because residents have been more adherent to mask mandates, Perry speculates. Overall, the United Kingdom has seen 1 in 7 residents infected with COVID-19, according to an ongoing New York Times analysis.
Perry says many UK residents are now coping with lingering complications of COVID-19, and the NHS is working to address these issues while seeking to reestablish normal services across the health care spectrum. "Currently, we're in a quieter phase in comparison with other stages" of the pandemic, he says.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.